Limited coverage drugs – tocilizumab (for giant cell arteritis)

Last updated on September 27, 2024

Generic name

tocilizumab                                                          

Strength

162 mg/0.9 mL

Form

pre-filled syringe

Special Authority criteria

Approval period

For the treatment of giant cell arteritis (GCA), according to criteria detailed in Special Authority Request form HLTH 5496 and when prescribed by a rheumatologist or ophthalmologist

1 year

Practitioner exemptions

  • None

Special notes

  • None

Special Authority requests